| Předmět: |
|
| Zdroj: |
Pharma Business Week; 6/21/2024, p992-992, 1p |
| Abstrakt: |
Cue Biopharma Inc. has been issued a patent for methods of modulating an immune response. The patent involves administering a combination of an immune checkpoint inhibitor and a protein to treat individuals with cancer that expresses a human papilloma virus-16 (HPV16) E7 antigen. The protein is a homodimer of two multimeric polypeptides, each containing specific components such as an HPV16 E7 epitope and a major histocompatibility complex (MHC) class I heavy chain polypeptide. The patent also includes methods of treatment using different variants of the protein and specific dosages. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
